Widespread use of alternative payment models may improve the quality of breast and colorectal cancer screening programs. READ MORE
Re-excision rates following breast-conserving surgery have significantly declined in the wake of professional society guideline implementation.
Women with HER2-positive and triple-negative breast cancer have an elevated risk of developing brain metastasis regardless of active systemic treatment receipt.
The average cost during the initial phase of breast cancer care for Medicare fee-for-service beneficiaries was $28,075 – $13,344 of which went toward physician services and $7456 for outpatient services.
A recent survey found that approximately 33% of patients with breast cancer forego their physician-recommended adjuvant therapies due to distrust in medical institutions and insurers.